申请人:BEIJING SHENOGEN PHARMA GROUP LTD.
公开号:US20150011618A1
公开(公告)日:2015-01-08
The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-α36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.
本发明涉及式(I)的香豆素化合物,其药学上可接受的盐、前药以及含有该化合物的组合物等。它们可用于调节雌激素受体ER-α36的功能,预防和/或治疗与雌激素相关的疾病,如乳腺癌、白血病、肝癌等。